ASCO: AstraZeneca Posts Strong Survival Data for Tagrisso in NSCLC Patients

Final results from the Phase III ADAURA study showed that AstraZeneca’s Tagrisso (osimertinib), when given after surgery, could strongly improve survival among post-operative adult non-small cell lung cancer patients carrying mutations in the EGFR gene, according to data presented Sunday at the 2023 American Society of Clinical Oncology annual meeting.